Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme

Journal of Intellectual Disability Research

Volumn 57, Issue 2, 2013, Pages 161-171

  Khanna, R ^a   Jariwala, K ^a   West Strum, D ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Autism; Costs; Medicaid; Psychotropic drugs

Indexed keywords

ANXIOLYTIC AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CHILD; COMORBIDITY; DRUG COST; DRUG USE; FEMALE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AUTISTIC DISORDER; CHILD; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEE-FOR-SERVICE PLANS; FEMALE; HUMANS; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; MISSISSIPPI; PREVALENCE; PSYCHOTROPIC DRUGS; UNITED STATES; YOUNG ADULT;

EID: 84872125027     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2012.01563.x     Document Type: Article

References (25)

1. Aman M. G. (2005) Treatment planning for patients with autism spectrum disorders. The Journal of Clinical Psychiatry 66, 38-45.
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revised. American Psychiatric Association, Washington, DC.
3. Billstedt E., Gillberg I. C. & Gillberg C. (2005) Autism after adolescence: population-based 13- to 22-year follow-up study of 120 individuals with autism diagnosed in childhood. Journal of Autism and Developmental Disorders 35, 351-60.
4. Esbensen A. J., Greenberg J. S., Seltzer M. M. & Aman M. G. (2009) A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders 39, 1339-49.
5. Findling R. L. (2005) Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. The Journal of Clinical Psychiatry 66, 26-31.
6. Fombonne E. (2003) Epidemiological surveys of autism and other pervasive developmental disorders: an update. Journal of Autism and Developmental Disorders 33, 365-82.
7. Gillberg C. & Schaumann H. (1981) Infantile autism and puberty. Journal of Autism and Developmental Disorders 11, 365-71.
8. Holburn C. S. (2008) Detrimental effects of overestimating the occurrence of autism. Journal of Intellectual & Developmental Disability 46, 243-6.
9. Jacobson J. W., Mulick J. A. & Green G. (1998) Cost benefit estimates for early intensive behavioral intervention for young children with autism - general model and single state case. Behavioral Interventions 13, 201-26.
10. Kogan M. D., Blumberg S. J., Schieve L. A., Boyle C. A., Perrin J. M., Ghandour R. M. etal. (2009) Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124, 1395-403.
11. Kutcher S. P. (1997) Psychopharmacologic Treatment of Autism and Mental Retardation. Child and Adolescent Psychopharmacology. WB Saunders Company, Philadelphia, PA.
12. Langworthy-Lam K. S., Aman M. G. & Van Bourgondien M. E. (2002) Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 12, 311-21.
13. Mandell D. S., Listerud J., Levy S. E. & Pinto-Martin J. A. (2002) Race differences in the age at diagnosis among Medicaid-eligible children with autism. Journal of the American Academy of Child and Adolescent Psychiatry 41, 1447-53.
14. Mandell D. S., Morales K. H., Marcus S. C., Stahmer A. C., Doshi J. & Polsky D. E. (2008) Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121, e441-8.
15. Mayes S. D. & Calhoun S. L. (1999) Symptoms of autism in young children and correspondence with the DSM. Infants and Young Children 12, 90-7.
16. McPheeters M. L., Warren Z., Sathe N., Bruzek J. L., Krishnaswami S., Jerome R. N. etal. (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127, e1312-21.
17. Nicholas J. S., Charles J. M., Carpenter L. A., King L. B., Jenner W. & Spratt E. G. (2008) Prevalence and characteristics of children with autism-spectrum disorders. Annals of Epidemiology 18, 130-6.
18. Oswald D. P. & Sonenklar N. A. (2007) Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology 17, 348-55.
19. Périsse D., Amiet C., Consoli A., Thorel M. V., Gourfinkel-An I., Bodeau N. etal. (2010) Risk factors of acute behavioral regression in psychiatrically hospitalized adolescents with autism. Journal of the Canadian Academy of Child and Adolescent Psychiatry 19, 100-8.
20. Posey D. J., Stigler K. A., Erickson C. A. & McDougle C. J. (2008) Antipsychotics in the treatment of autism. The Journal of Clinical Investigation 118, 6-14.
21. Rosenberg R. E., Mandell D. S., Farmer J. E., Law J. K., Marvin A. R. & Law P. A. (2010) Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorders 40, 342-51.
22. Rubin D. M., Feudtner C., Localio R. & Mandell D. S. (2009) State variation in psychotropic medication use by foster care children with autism spectrum disorder. Pediatrics 124, e305-12.
23. Ruble L. A., Heflinger C. A., Renfrew J. W. & Saunders R. C. (2005) Access and service use by children with autism spectrum disorders in Medicaid Managed Care. Journal of Autism and Developmental Disorders 35, 3-13.
24. Szpir M. (2006) Tracing the origins of autism: a spectrum of new studies. Environmental Health Perspectives 114, A412-18.
25. Tsai L. Y. (1999) Psychopharmacology in autism. Psychosomatic Medicine 61, 651-65.